
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is a global company that produces medical devices for use in various procedures and treatments. They have a diverse product portfolio, strong profitability, and potential for growth through new products and recent acquisitions. While there are risks such as potential macroeconomic challenges and competition, their sales growth and profitability metrics support a positive outlook. The company's recent announcement of reduced growth expectations for their Watchman LAAC franchise may have impacted investor confidence, but the company's long-range plan shows potential for continued growth.
Bears say
Boston Scientific is facing challenges in its key product markets, such as slower growth in Watchman procedures and losing market share in Farapulse PFA and Urology. These challenges have led management to revise downward its full-year revenue guidance and lower its Q2 outlook, causing near-term negative sentiment. Additionally, while Boston Scientific maintains bottom-line expectations, there are concerns about their ability to offset the lower revenue expectations and the potential for a Long-Range Plan reset. However, Boston Scientific is undervalued and has a strong product pipeline and impressive profitability metrics, which could lead to margin expansion and double-digit adjusted EPS growth.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares